IRAK1 and nasopharyngeal carcinoma: IRAK1 expression is increased in breast cancer paclitaxel-resistant cell lines, an IRAK1 inhibitor reverses paclitaxel resistance in triple-negative breast cancer, and IRAK1 is also a potential therapeutic target for paclitaxel resistance in nasopharyngeal carcinoma (39).